Pulmonx (Redwood City, CA) a commercial-stage medical device company focused on minimally invasive devices for the diagnosis and treatment of COPD and other pulmonary disorders, closed a $32M Series C financing. Participants include HealthCap, Kleiner Perkins Caufield & Byers, De Novo Ventures, Latterell Venture Partners, MedVenture Associates, Montreux Equity Partners and Posco BioVentures.

Pearl Therapeutics (Redwood City, CA) a clinical-stage pharma company focused on metered dose inhaler products for the treatment of COPD and asthma, closed a $15M Series C financing. Participants include Clarus Ventures, New Leaf Venture Partners and 5AM Ventures.

MicroCHIPS (Bedford, MA) a development-stage medical device company focused on implantable drug delivery and biosensing for diabetes and osteoporosis, closed a $16.5M Series C financing. Participants include InterWest Partners, Polaris Venture Partners, Novartis Venture Fund, Flybridge Capital Partners, Medtronic, Saints Capital, Intersouth Partners, Care Capital and CSK Venture Capital.

Tandem Diabetes Care (San Diego, CA) a development-stage medical device company focused on insulin pump technology, closed a $30.8M Series C financing, bringing the total round to $52.3M. Participants include HLM Venture Partners, Domain Associates, TPG Biotech, Delphi Ventures and Kearny Venture Partners.

CicuLite (Saddle Brook, NJ) a clinical-stage medical device company focused on minimally invasive implantable devices for chronic heart failure, closed a $32.5M Series C financing. Participants include Forbion Capital Partners, Crédit Agricole Private Equity, Foundation Medical Partners and Oxford Bioscience Partners.

CalciMedica (La Jolla, CA) a preclinical-stage small molecule company focused on autoimmune and inflammatory via the inhibition of calcium release-activated calcium (CRAC) channels, closed a $5M Series C financing, bringing the total round up to $9M. Participants include Biogen Idec, Sanderling Ventures and SR One.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Circassia (United Kingdom) a clinical-stage specialty biopharmaceutical focused on therapeutic T-cell vaccines for allergies and organ transplant rejection, closed a $25M Series C financing. Participants include Imperial Innovations, Invesco Perpetual and Lansdowne Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

SantoSolve (Norway) a clinical-stage biopharmaceutical company focused on topical analgesic products based on non-radioactive strontium for various pain conditions, closed a $5.5M Series C financing. Participants include Teknoinvest, InnovationsKapital and Investinor.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Cellerix (Spain) a clinical-stage biopharma company focused on adult stem cell therapies for Crohn’s and other GI diseases, closed a $37.7M Series C financing. Participants include Ysios Capital Partners, Ventech, Roche Venture Fund and Novartis Venture Fund.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Oxagen (United Kingdom) a clinical-stage biopharmaceutical company focused on asthma and allergic rhinitis based drug company focused on inflammation, closed a $25.M Series C financing. Participants include MPM Capital, SV Life Sciences, Advent Ventures, Bessemer Venture Partners, Omega Ventures, Abingworth, International Bio Trust, Red Abbey Venture Partners and Wellcome Trust.

Note: 2009 Year-in-Review Trend Analysis Coming [...]